<DOC>
	<DOCNO>NCT00030290</DOCNO>
	<brief_summary>RATIONALE : Highly focus ultrasound energy may able kill cancer cell heat tumor without affect surround tissue . PURPOSE : Phase I trial study effectiveness focus ultrasound energy treat patient prostate cancer spread beyond prostate .</brief_summary>
	<brief_title>Ultrasound Treating Patients With Prostate Cancer Confined Prostate</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability Sonablate focus ultrasonic wave purpose selectively destroy prostate cancer tissue , resultant drop PSA level 0.5 ng/mL negative biopsy cancer cell , patient organ-confined prostate cancer . OUTLINE : This multicenter study . A probe insert rectum . High-intensity focus ultrasound ( HIFU ) energy use Sonablate system deliver prostate tissue approximately 2-3 hour . Patients residual cancer lesion ( biopsy ) , PSA great 0.5 ng/mL increase PSA level take least 2 month apart , visible prostate tissue ultrasound , local distant metastasis day 90 undergo retreatment HIFU . Patients follow 2 , 14 , 30 , 90 , 180 day . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm organconfined prostate cancer ( clinical stage T1 T2 ) Pretreatment prostate weight less 40 g Gleason score great 7 PSA great 10 ng/mL No significant intravesical median lobe ( great 2 cm ) ultrasound Able visualize prostate gland adequately transrectal ultrasound image No prostate calcification great 5 mm No metastases bone scan PATIENT CHARACTERISTICS : Age : 40 80 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No bleed disorder determine abnormal PT PTT Renal : No active urinary tract infection No history urinary bladder neck contracture Other : No prior allergy latex No Anesthesia Surgical Assignment category IV great No interest future fertility No history inflammatory bowel disease No concurrent major debilitate illness No prior concurrent malignancy except skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy prostate cancer Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : At least 3 month since prior hormonal therapy ( include finasteride ) prostate cancer Radiotherapy : No prior radiotherapy prostate cancer Surgery : No prior transurethral resection prostate No prior urethral stent No prior major rectal surgery Other : No prior cryotherapy prostate cancer No prior thermotherapy No prior therapy prostate cancer No concurrent warfarin anticoagulant</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>